FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123161719> ?p ?o ?g. }

• W2123161719 endingPage "212" @default.
• W2123161719 startingPage "204" @default.
• W2123161719 abstract "Urotensin-II (U-II) is a cyclic peptide now described as the most potent vasoconstrictor known. U-II binds to a specific G protein-coupled receptor, formerly the orphan receptor GPR14, now renamed urotensin receptor (UT receptor), and present in mammalian species. Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt) is a new potent and specific antagonist of the human UT receptor. ACT-058362 antagonizes the specific binding of ¹²⁵I-labeled U-II on natural and recombinant cells carrying the human UT receptor with a high affinity in the low nanomolar range and a competitive mode of antagonism, revealed only with prolonged incubation times. ACT-058362 also inhibits U-II-induced calcium mobilization and mitogen-activated protein kinase phosphorylation. The binding inhibitory potency of ACT-058362 is more than 100-fold less on the rat than on the human UT receptor, which is reflected in a pD′₂ value of 5.2 for inhibiting contraction of isolated rat aortic rings induced by U-II. In functional assays of short incubation times, ACT-058362 behaves as an apparent noncompetitive inhibitor. In vivo, intravenous ACT-058362 prevents the no-reflow phenomenon, which follows renal artery clamping in rats, without decreasing blood pressure and prevents the subsequent development of acute renal failure and the histological consequences of ischemia. In conclusion, the in vivo efficacy of the specific UT receptor antagonist ACT-058362 reveals a role of endogenous U-II in renal ischemia. As a selective renal vasodilator, ACT-058362 may be effective in other renal diseases." @default.
• W2123161719 created "2016-06-24" @default.
• W2123161719 creator A5005230659 @default.
• W2123161719 creator A5020829373 @default.
• W2123161719 creator A5024408129 @default.
• W2123161719 creator A5030689957 @default.
• W2123161719 creator A5030736413 @default.
• W2123161719 creator A5031041658 @default.
• W2123161719 creator A5035664132 @default.
• W2123161719 creator A5038904441 @default.
• W2123161719 creator A5045790841 @default.
• W2123161719 creator A5048581555 @default.
• W2123161719 creator A5056010036 @default.
• W2123161719 creator A5057121083 @default.
• W2123161719 creator A5059205735 @default.
• W2123161719 creator A5059376462 @default.
• W2123161719 creator A5066031416 @default.
• W2123161719 creator A5068728897 @default.
• W2123161719 creator A5076782599 @default.
• W2123161719 creator A5079414665 @default.
• W2123161719 creator A5080887450 @default.
• W2123161719 date "2004-05-14" @default.
• W2123161719 modified "2023-10-16" @default.
• W2123161719 title "Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System" @default.
• W2123161719 cites W1486256755 @default.
• W2123161719 cites W1963734953 @default.
• W2123161719 cites W1982838274 @default.
• W2123161719 cites W1993518928 @default.
• W2123161719 cites W1995498107 @default.
• W2123161719 cites W2004944698 @default.
• W2123161719 cites W2020466261 @default.
• W2123161719 cites W2021240007 @default.
• W2123161719 cites W2027724929 @default.
• W2123161719 cites W2033975634 @default.
• W2123161719 cites W2045988967 @default.
• W2123161719 cites W2047456641 @default.
• W2123161719 cites W2049784193 @default.
• W2123161719 cites W2051650556 @default.
• W2123161719 cites W2056735945 @default.
• W2123161719 cites W2063108849 @default.
• W2123161719 cites W2075733166 @default.
• W2123161719 cites W2082023643 @default.
• W2123161719 cites W2085452490 @default.
• W2123161719 cites W2085855801 @default.
• W2123161719 cites W2094729588 @default.
• W2123161719 cites W2095243948 @default.
• W2123161719 cites W2110707664 @default.
• W2123161719 cites W2125361242 @default.
• W2123161719 cites W2127012371 @default.
• W2123161719 cites W2130943352 @default.
• W2123161719 cites W2135813820 @default.
• W2123161719 cites W2140228755 @default.
• W2123161719 cites W2145043050 @default.
• W2123161719 cites W2152996717 @default.
• W2123161719 cites W2153058326 @default.
• W2123161719 cites W2317695933 @default.
• W2123161719 cites W2331271152 @default.
• W2123161719 doi "https://doi.org/10.1124/jpet.104.068320" @default.
• W2123161719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15146030" @default.
• W2123161719 hasPublicationYear "2004" @default.
• W2123161719 type Work @default.
• W2123161719 sameAs 2123161719 @default.
• W2123161719 citedByCount "117" @default.
• W2123161719 countsByYear W21231617192012 @default.
• W2123161719 countsByYear W21231617192013 @default.
• W2123161719 countsByYear W21231617192014 @default.
• W2123161719 countsByYear W21231617192015 @default.
• W2123161719 countsByYear W21231617192016 @default.
• W2123161719 countsByYear W21231617192017 @default.
• W2123161719 countsByYear W21231617192018 @default.
• W2123161719 countsByYear W21231617192019 @default.
• W2123161719 countsByYear W21231617192020 @default.
• W2123161719 countsByYear W21231617192021 @default.
• W2123161719 countsByYear W21231617192022 @default.
• W2123161719 countsByYear W21231617192023 @default.
• W2123161719 crossrefType "journal-article" @default.
• W2123161719 hasAuthorship W2123161719A5005230659 @default.
• W2123161719 hasAuthorship W2123161719A5020829373 @default.
• W2123161719 hasAuthorship W2123161719A5024408129 @default.
• W2123161719 hasAuthorship W2123161719A5030689957 @default.
• W2123161719 hasAuthorship W2123161719A5030736413 @default.
• W2123161719 hasAuthorship W2123161719A5031041658 @default.
• W2123161719 hasAuthorship W2123161719A5035664132 @default.
• W2123161719 hasAuthorship W2123161719A5038904441 @default.
• W2123161719 hasAuthorship W2123161719A5045790841 @default.
• W2123161719 hasAuthorship W2123161719A5048581555 @default.
• W2123161719 hasAuthorship W2123161719A5056010036 @default.
• W2123161719 hasAuthorship W2123161719A5057121083 @default.
• W2123161719 hasAuthorship W2123161719A5059205735 @default.
• W2123161719 hasAuthorship W2123161719A5059376462 @default.
• W2123161719 hasAuthorship W2123161719A5066031416 @default.
• W2123161719 hasAuthorship W2123161719A5068728897 @default.
• W2123161719 hasAuthorship W2123161719A5076782599 @default.
• W2123161719 hasAuthorship W2123161719A5079414665 @default.
• W2123161719 hasAuthorship W2123161719A5080887450 @default.
• W2123161719 hasConcept C150903083 @default.
• W2123161719 hasConcept C170493617 @default.
• W2123161719 hasConcept C185592680 @default.

• next